Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

5
results for

"Jung Il Lee"

Article category

Keywords

Publication year

"Jung Il Lee"

Original Articles

Hepatic neoplasm

Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B
Won Sohn, Ju-Yeon Cho, Ji Hoon Kim, Jung Il Lee, Hyung Joon Kim, Min-Ah Woo, Sin-Ho Jung, Yong-Han Paik
Clin Mol Hepatol 2017;23(2):170-178.
Published online May 16, 2017
DOI: https://doi.org/10.3350/cmh.2016.0086
Background/Aims
This study aimed to develop and validate a risk prediction model for the development of hepatocellular carcinoma (HCC) in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B (CHB).
Methods
We investigated 2,061 Korean treatment-naïve patients with CHB treated with entecavir as an initial therapy. A risk score model for HCC development was developed based on multivariable Cox regression model in a single center (n=990) and was validated using the time-dependent area under the receiver operating characteristic curve (AUROC) in three other centers (n=1,071). The difference of HCC development among risk groups (low, intermediate, and high) categorized by risk score was also investigated.
Results
The cumulative incidence rates of HCC at 5 years were 11.2% and 8.9% in the testing and validation cohorts, respectively. HCC-Risk Estimating Score in CHB patients Under Entecavir (HCC-RESCUE) is formulated as (age+15×gender [female=0 / male=1]+23×cirrhosis [absence=0 / presence=1]). The AUROCs at 1 year, 3 years, and 5 years were 0.82, 0.81, and 0.81, respectively, in the validation cohort. A significant difference of HCC development in each risk group was determined by the 5-year HCC risk score in the validation cohort (low risk group, 2.1%; intermediate risk group, 9.3%; high risk group, 41.2%, p<0.001).
Conclusions
The study presents a new risk score model with a good ability to predict HCC development and determine high risk patients for HCC development consisting of readily available clinical factors in treatment-naïve CHB patients receiving entecavir.

Citations

Citations to this article as recorded by  Crossref logo
  • Behaviour‐Based Predictive Scores of Hepatocellular Carcinoma in People With Chronic Hepatitis B (ANRS CO22 HEPATHER)
    Clémence Ramier, Camelia Protopopescu, Vincent Di Beo, Lucia Parlati, Fabienne Marcellin, Fabrice Carrat, Tarik Asselah, Marc Bourlière, Patrizia Carrieri
    Liver International.2025;[Epub]     CrossRef
  • Validation Study of Scores Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Nucleos(t)ide Analogues
    Jun Inoue, Shinichiro Minami, Kazumichi Abe, Mami Kida, Hiroaki Haga, Chikara Iino, Hiroshi Numao, Hidekatsu Kuroda, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Masazumi Onuki, Satoko Sawahashi, Keishi Ouchi, Kengo Watanabe, Takehiro Akahane, Tomoo Kobay
    Journal of Viral Hepatitis.2025;[Epub]     CrossRef
  • A Review of Risk Prediction Model for Hepatocellular Carcinoma in Chronic Hepatitis B
    Jiwon Yang, Mark D. Muthiah, Won-Mook Choi
    Current Hepatology Reports.2025;[Epub]     CrossRef
  • MR elastography-based prediction of development of hepatocellular carcinoma in patients with chronic hepatitis B with sustained virological response
    Haimei Chen, Jie Zhu, Jinhui Zhou, Ziying Yin, Jun Chen, Sudhakar K. Venkatesh, Meng Yin, Richard L. Ehman, Jin Wang
    European Radiology.2025; 35(12): 8032.     CrossRef
  • Novel blood signature for hepatocellular carcinoma screening
    K.-M. Chueng, K.-N. Kwok, S.J.-L. Lam, H.-S. Lam, S.-M. Yip, S. Lam, O.-P. Chiu, A.K.-Y. Chan, H.H.-W. Liu, S.K.-K. Ng, L. Sutanto, J.C.K. Yung, H.-L. Leung, P.Y.-M. Woo, H.H.-Y. Yiu, D.C.C. Lam
    ESMO Gastrointestinal Oncology.2025; 9: 100185.     CrossRef
  • Current and new strategies for hepatocellular carcinoma surveillance
    Natchaya Polpichai, Chongkonrat Maneenil, Pojsakorn Danpanichkul, Chitchai Rattananukrom, Ashok Choudhury, Yu Jun Wong, Pimsiri Sripongpun, Suthat Liangpunsakul, Apichat Kaewdech
    Gastroenterology Report.2025;[Epub]     CrossRef
  • Score-based prediction model for female hepatocellular carcinoma surveillance in asymptotic HBsAg carriers: a multicenter cohort study in China
    Mengdi Cao, Maomao Cao, Changfa Xia, Fan Yang, Xinxin Yan, Siyi He, Shaoli Zhang, Yi Teng, Qianru Li, Nuopei Tan, Jiachen Wang, Chunfeng Qu, Wanqing Chen
    Journal of the National Cancer Center.2025; 5(5): 493.     CrossRef
  • Dynamic changes in liver stiffness measurement by 2D shear-wave elastography predict hepatocellular carcinoma in patients with chronic hepatitis B and well-controlled viremia: a retrospective study
    Nana Wang, Yuankai Wu, Mingyue Xiao, Yusheng Jie, Jinfen Wang, Manli Wu, Jiaxin Chen, Liuping Sha, Zhongzhen Su, Yutian Chong, Lili Wu
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C
    Yu Rim Lee, Hyun Young Woo, Young Oh. Kweon, Won Young Tak, Se Young Jang, Jung Gil Park, Min Kyu Kang, Jeong Eun Song, Byoung Kuk Jang, Changhyeong Lee, Byung Seok Kim, Jae Seok Hwang, Woo Jin Chung, Jeong Heo, Nae‐Yun Heo, Seung Ha Park, Jun Sik Yoon, J
    Journal of Gastroenterology and Hepatology.2025; 40(10): 2568.     CrossRef
  • Early screening for liver cancer must be performed
    Zi-Han Liu, Wen-Jun Wang, Shuang-Suo Dang
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • A prediction nomogram for hepatitis B virus-associated hepatocellular carcinoma
    Yijin Zhang, Gang Wan, Hongjie Li, Lili Gao, Nan Liu, Ping Gao, Yaping Liu, Xuesong Gao, Xuefei Duan
    Scandinavian Journal of Gastroenterology.2024; 59(1): 70.     CrossRef
  • A Liver Stiffness–Based Etiology-Independent Machine Learning Algorithm to Predict Hepatocellular Carcinoma
    Huapeng Lin, Guanlin Li, Adèle Delamarre, Sang Hoon Ahn, Xinrong Zhang, Beom Kyung Kim, Lilian Yan Liang, Hye Won Lee, Grace Lai-Hung Wong, Pong-Chi Yuen, Henry Lik-Yuen Chan, Stephen Lam Chan, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim, Terr
    Clinical Gastroenterology and Hepatology.2024; 22(3): 602.     CrossRef
  • Applicability of Risk Scores to an Indian Cohort of Hepatitis B-Related Hepatocellular Carcinoma Patients
    Gautam Ray
    Journal of Clinical and Experimental Hepatology.2024; 14(4): 101370.     CrossRef
  • Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy
    Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Sang Hoon Ahn, Won Kim, Jin Mo Yang, Jae Young Jang, Yong Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Joo Hyun Sohn, Jin Woo Lee, Sung Jae Park, Sun Young Yim, Jin Kyung Park, Soon
    Cancers.2024; 16(5): 887.     CrossRef
  • Prognostic significance of dynamic changes in liver stiffness measurement in patients with chronic hepatitis B and compensated advanced chronic liver disease
    Hongsheng Yu, Yinan Huang, Mingkai Li, Hao Jiang, Bilan Yang, Xiaoli Xi, Abdukyamu Smayi, Bin Wu, Yidong Yang
    Journal of Gastroenterology and Hepatology.2024; 39(10): 2169.     CrossRef
  • Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma
    Lung-Yi Mak
    Journal of Liver Cancer.2024; 24(2): 145.     CrossRef
  • Risk predictive model for the development of hepatocellular carcinoma before initiating long‐term antiviral therapy in patients with chronic hepatitis B virus infection
    Junjie Chen, Tienan Feng, Qi Xu, Xiaoqi Yu, Yue Han, Demin Yu, Qiming Gong, Yuan Xue, Xinxin Zhang
    Journal of Medical Virology.2024;[Epub]     CrossRef
  • Risk stratification and early detection biomarkers for precision HCC screening
    Yi‐Te Lee, Naoto Fujiwara, Ju Dong Yang, Yujin Hoshida
    Hepatology.2023; 78(1): 319.     CrossRef
  • Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment
    Jun Li, Xiao-Qin Dong, Li-Hua Cao, Zhan-Qing Zhang, Wei-Feng Zhao, Qing-Hua Shang, Da-Zhi Zhang, An-Lin Ma, Qing Xie, Hong-Lian Gui, Guo Zhang, Ying-Xia Liu, Jia Shang, Shi-Bin Xie, Yi-Qi Liu, Chi Zhang, Gui-Qiang Wang, Hong Zhao
    Frontiers in Cellular and Infection Microbiology.2023;[Epub]     CrossRef
  • HCC prediction models in chronic hepatitis B patients receiving entecavir or tenofovir: a systematic review and meta-analysis
    Xiaolan Xu, Lushun Jiang, Yifan Zeng, Liya Pan, Zhuoqi Lou, Bing Ruan
    Virology Journal.2023;[Epub]     CrossRef
  • Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
    Beom Kyung Kim, Sang Hoon Ahn
    Journal of the Formosan Medical Association.2023; 122(12): 1238.     CrossRef
  • Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection
    Chih-Lin Lin, Jia-Horng Kao
    Clinical and Molecular Hepatology.2023; 29(3): 605.     CrossRef
  • A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B
    Hye Won Lee, Hwiyoung Kim, Taeyun Park, Soo Young Park, Young Eun Chon, Yeon Seok Seo, Jae Seung Lee, Jun Yong park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim
    Liver International.2023; 43(8): 1813.     CrossRef
  • Improving prediction of hepatocellular carcinoma in chronic hepatitis B by machine learning: Productive relationship of medicine with computer science
    Terry C. F. Yip, Cihan Yurdaydin
    Liver International.2023; 43(8): 1626.     CrossRef
  • Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States
    Hyun-seok Kim, Xian Yu, Jennifer Kramer, Aaron P. Thrift, Pete Richardson, Yao-Chun Hsu, Avegail Flores, Hashem B. El-Serag, Fasiha Kanwal
    Journal of Hepatology.2022; 76(2): 294.     CrossRef
  • An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B
    Hwi Young Kim, Pietro Lampertico, Joon Yeul Nam, Hyung-Chul Lee, Seung Up Kim, Dong Hyun Sinn, Yeon Seok Seo, Han Ah Lee, Soo Young Park, Young-Suk Lim, Eun Sun Jang, Eileen L. Yoon, Hyoung Su Kim, Sung Eun Kim, Sang Bong Ahn, Jae-Jun Shim, Soung Won Jeon
    Journal of Hepatology.2022; 76(2): 311.     CrossRef
  • An MRI-Based Radiomic Model for Individualized Prediction of Hepatocellular Carcinoma in Patients With Hepatitis B Virus-Related Cirrhosis
    Yichen Wei, Jie Gong, Xin He, Bo Liu, Tiejun Liu, Shuohui Yang, Zhipeng Zhou, Lingyan Liang, Songhua Zhan, Ziqiang Xia, Gaoxiong Duan, Bin Lin, Qiuli Han, Shasha Li, Wei Qin, Perry J. Pickhardt, Demao Deng
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis
    Ze-Hong Huang, Gui-Yang Lu, Ling-Xian Qiu, Guo-Hua Zhong, Yue Huang, Xing-Mei Yao, Xiao-Hui Liu, Shou-Jie Huang, Ting Wu, Quan Yuan, Ying-Bin Wang, Ying-Ying Su, Jun Zhang, Ning-Shao Xia
    BMC Cancer.2022;[Epub]     CrossRef
  • Hepatitis B Virus-Associated Hepatocellular Carcinoma
    Giacomo Emanuele Maria Rizzo, Giuseppe Cabibbo, Antonio Craxì
    Viruses.2022; 14(5): 986.     CrossRef
  • External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B
    Thierry Poynard, Jean Marc Lacombe, Olivier Deckmyn, Valentina Peta, Sepideh Akhavan, Fabien Zoulim, Victor de Ledinghen, Didier Samuel, Philippe Mathurin, Vlad Ratziu, Dominique Thabut, Chantal Housset, Hélène Fontaine, Stanislas Pol, Fabrice Carrat
    Gastro Hep Advances.2022; 1(4): 604.     CrossRef
  • The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection
    Jung Hwan Yu, Soon Gu Cho, Young-Joo Jin, Jin-Woo Lee
    Clinical and Molecular Hepatology.2022; 28(3): 351.     CrossRef
  • Effect of entecavir and tenofovir disoproxil fumarate on hepatocellular carcinoma in subjects with chronic hepatitis B: a meta-analysis
    Sara M. Tony, Mohamed E. A. Shaaban, Ahmed I. M. Mohamed, Mohamed E. A. Abdelrahim
    Beni-Suef University Journal of Basic and Applied Sciences.2022;[Epub]     CrossRef
  • A Mac-2 Binding Protein Glycosylation Isomer-Based Risk Model Predicts Hepatocellular Carcinoma in HBV-Related Cirrhotic Patients on Antiviral Therapy
    Chien-Hung Chen, Tsung-Hui Hu, Jing-Houng Wang, Hsueh-Chou Lai, Chao-Hung Hung, Sheng-Nan Lu, Cheng-Yuan Peng
    Cancers.2022; 14(20): 5063.     CrossRef
  • Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
    Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim
    Diagnostics.2022; 13(1): 3.     CrossRef
  • Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir
    Jin Won Chang, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yeon Seok Seo, Han Ah Lee, Mi Na Kim, Yu Rim Lee, Seong Gyu Hwang, Kyu Sung Rim, Soon Ho Um, Won Young Tak, Young Oh Kweon, Soo Young Park, Seung Up Kim
    Journal of Viral Hepatitis.2021; 28(1): 95.     CrossRef
  • Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control
    Pierre Nahon, Erwan Vo Quang, Nathalie Ganne-Carrié
    Journal of Clinical Medicine.2021; 10(2): 353.     CrossRef
  • Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update
    James Lok, Kosh Agarwal
    Viruses.2021; 13(7): 1333.     CrossRef
  • Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it?
    Coskun Ozer Demirtas, Maurizia Rossana Brunetto
    World Journal of Gastroenterology.2021; 27(33): 5536.     CrossRef
  • Prediction models for development of hepatocellular carcinoma in chronic hepatitis B patients
    Jiang Guo, Xue-Song Gao
    World Journal of Clinical Cases.2021; 9(14): 3238.     CrossRef
  • Validation of the HCC‐RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy
    Fatih Güzelbulut, Pınar Gökçen, Güray Can, Gupse Adalı, Ayça Gökçen Değirmenci Saltürk, Özgür Bahadır, Kamil Özdil, Hamdi Levent Doğanay
    Journal of Viral Hepatitis.2021; 28(5): 826.     CrossRef
  • Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B
    George V. Papatheodoridis, George N. Dalekos, Ramazan Idilman, Vana Sypsa, Florian Van Boemmel, Maria Buti, Jose Luis Calleja, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Margarita Papatheodoridi, Nikolaos Gatselis, Rhea Veelken, Marta Lopez-G
    JHEP Reports.2021; 3(3): 100290.     CrossRef
  • Screening for Hepatocellular Carcinoma in Patients with Hepatitis B
    Yashasavi Sachar, Mayur Brahmania, Renumathy Dhanasekaran, Stephen E. Congly
    Viruses.2021; 13(7): 1318.     CrossRef
  • Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future Perspective
    Yao-Chun Hsu, Cheng-Hao Tseng, Yen-Tsung Huang, Hwai-I Yang
    Seminars in Liver Disease.2021; 41(03): 285.     CrossRef
  • Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy
    Seung Up Kim, Yeon Seok Seo, Han Ah Lee, Mi Na Kim, Eun Hwa Kim, Ha Yan Kim, Yu Rim Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seong Gyu Hwang, Kyu Sung Rim, Soon Ho Um, Won Young Tak, Young Oh Kweon, Beom Kyung Kim, Soo
    Clinical Gastroenterology and Hepatology.2020; 18(3): 693.     CrossRef
  • Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B
    Thodoris Voulgaris, Margarita Papatheodoridi, Pietro Lampertico, George V. Papatheodoridis
    Liver International.2020; 40(3): 484.     CrossRef
  • Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis
    Xinhui Wang, Xiaoli Liu, Zhibo Dang, Lihua Yu, Yuyong Jiang, Xianbo Wang, Zhiyun Yan
    Gut and Liver.2020; 14(2): 232.     CrossRef
  • Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review
    Cheng‐Hao Tseng, Chao‐Ming Tseng, Jia‐Ling Wu, Yao‐Chun Hsu, Hashem B. El-Serag
    Journal of Gastroenterology and Hepatology.2020; 35(10): 1684.     CrossRef
  • Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review
    Mohamed A Abd El Aziz, Rodolfo Sacco, Antonio Facciorusso
    Antiviral Chemistry and Chemotherapy.2020; 28: 204020662092133.     CrossRef
  • Obstacles and opportunities in the prevention and treatment of HBV-related hepatocellular carcinoma
    Yong Liao
    Genes & Diseases.2020; 7(3): 291.     CrossRef
  • Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy
    Joon Yeul Nam, Dong Hyun Sinn, Junho Bae, Eun Sun Jang, Jin-Wook Kim, Sook-Hyang Jeong
    JHEP Reports.2020; 2(6): 100175.     CrossRef
  • Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine
    George V. Papatheodoridis, Thodoris Voulgaris, Margarita Papatheodoridi, W. Ray Kim
    Hepatology.2020; 72(6): 2197.     CrossRef
  • Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
    Naoto Fujiwara, Scott L. Friedman, Nicolas Goossens, Yujin Hoshida
    Journal of Hepatology.2018; 68(3): 526.     CrossRef
  • Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B
    Yao-Chun Hsu, Terry Cheuk-Fung Yip, Hsiu J. Ho, Vincent Wai-Sun Wong, Yen-Tsung Huang, Hashem B. El-Serag, Teng-Yu Lee, Ming-Shiang Wu, Jaw-Town Lin, Grace Lai-Hung Wong, Chun-Ying Wu
    Journal of Hepatology.2018; 69(2): 278.     CrossRef
  • Effect of Metabolic Syndrome on the Clinical Outcomes of Chronic Hepatitis B Patients with Nucleos(t)ide Analogues Treatment
    Nam Hee Kim, Yong Kyun Cho, Byung Ik Kim, Hong Joo Kim
    Digestive Diseases and Sciences.2018; 63(10): 2792.     CrossRef
  • Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy
    Ji Hyun Kim, Young Don Kim, Minjong Lee, Baek Gyu Jun, Tae Suk Kim, Ki Tae Suk, Seong Hee Kang, Moon Young Kim, Gab Jin Cheon, Dong Joon Kim, Soon Koo Baik, Dae Hee Choi
    Journal of Hepatology.2018; 69(5): 1066.     CrossRef
  • Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy
    Byeong G. Song, Dong H. Sinn, Sangah Chi, Kyunga Kim, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon S. Choi, Joon H. Lee, Kwang C. Koh, Seung W. Paik
    European Journal of Gastroenterology & Hepatology.2018; 30(12): 1447.     CrossRef
  • Development of a nomogram for screening of hepatitis B virus-associated hepatocellular carcinoma
    Jung Wha Chung, Eun Sun Jang, Jaihwan Kim, Sook-Hyang Jeong, Nayoung Kim, Dong Ho Lee, Kyung Ho Lee, Jin-Wook Kim
    Oncotarget.2017; 8(63): 106499.     CrossRef
  • 13,185 View
  • 239 Download
  • 65 Web of Science
  • Crossref

Viral hepatitis

Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study)
Hye Won Lee, Jun Yong Park, Beom Kyung Kim, Moon Young Kim, Jung Il Lee, Young Suk Kim, Ki Tae Yoon, Kwang-Hyub Han, Sang Hoon Ahn
Clin Mol Hepatol 2016;22(4):443-449.
Published online November 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0037
Background/Aims
It remains to be determined whether switching from adefovir (ADV) to tenofovir (TDF) provides better virological outcomes in patients exhibiting suboptimal responses to ADV plus nucleoside analogue (ADV+NA) therapy for NA-resistant chronic hepatitis B (CHB).
Methods
In this prospective trial, patients who showed partial responses (defined as serum hepatitis B virus [HBV] DNA >60 IU/mL) to ADV+NA therapy for NA resistance were randomly allocated to receive TDF plus NA (TDF+NA group, n=16) or to continue their current therapy (ADV+NA group, n=16). The primary end point was the proportion of patients with complete virological response (CVR, defined as serum HBV DNA <60 IU/mL) at 48 weeks.
Results
The median age was 52 years (16 men), and 28 were positive for hepatitis B e antigen (HBeAg). The baseline characteristics did not differ significantly between the two groups. The proportion with CVR was significantly higher in the TDF+NA group than in the ADV+NA group at 24 weeks (81.3% vs. 25.0%, P=0.001) and 48 weeks (87.5% vs. 37.5%, P=0.002). Furthermore, a decrease in the serum HBV DNA level of >2log10 IU/mL was more likely in the TDF+NA group at both 24 and 48 weeks (68.8% vs. 56.3%, P=0.014 vs. 81.3% vs. 56.3%, P=0.001, respectively). During the follow-up, the rate of HBeAg seroconversion was higher in the TDF+NA group than the ADV+NA group (12.5% vs. 6.25%, P=0.640), as was that for the hepatitis B surface antigen (6.25% vs. 0%, P=0.080). No serious adverse events due to antiviral agents occurred.
Conclusions
In patients exhibiting suboptimal responses to ADV+NA therapy for NA-resistant CHB, switching from ADV to TDF might provide better virological outcomes.

Citations

Citations to this article as recorded by  Crossref logo
  • Comparative efficacy and safety of pegylated interferon-alpha monotherapy vs combination therapies with entecavir or tenofovir in chronic hepatitis B patients
    Huiqing Liang, Xiaoting Zheng, Qianguo Mao, Jiaen Yang, Qingfa Ruan, Chuncheng Wu, Yaoyu Liu, Siyan Chen, Luyun Zhang, Manying Zhang, Hongli Zhuang, Li Lin, Shaodong Chen, Hyun Jin Kwun
    Microbiology Spectrum.2025;[Epub]     CrossRef
  • Predictive value of hepatic, hematological, and immunological markers and their temporal dynamics in chronic hepatitis B functional cure
    Jianyong Zeng, Caixia Zheng, Yincheng Zheng, Xiulan Xue, Benjamin M. Liu
    Microbiology Spectrum.2025;[Epub]     CrossRef
  • Entecavir versus tenofovir on the recurrence of hepatitis B–related HCC after liver transplantation: A multicenter observational study
    Deok-Gie Kim, YoungRok Choi, Jinsoo Rhu, Shin Hwang, Young Kyoung You, Dong-Sik Kim, Yang Won Nah, Bong-Wan Kim, Jai Young Cho, Koo Jeong Kang, Jae Do Yang, Donglak Choi, Dong Jin Joo, Myoung Soo Kim, Je Ho Ryu, Jae Geun Lee
    Liver Transplantation.2023; 29(12): 1272.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2022; 28(2): 276.     CrossRef
  • Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
    Byoung Kuk Jang
    Clinical and Molecular Hepatology.2020; 26(3): 312.     CrossRef
  • Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection
    Hye Won Lee, Jun Yong Park, Jin Woo Lee, Ki Tae Yoon, Chang Wook Kim, Hana Park, Young Seok Kim, Soon Ku Paik, Jung Il Lee, Beom Kyung Kim, Kwang-Hyub Han, Sang Hoon Ahn
    Clinical Gastroenterology and Hepatology.2019; 17(7): 1348.     CrossRef
  • Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B
    Dachuan Cai, Chen Pan, Weihua Yu, Shuangsuo Dang, Jia Li, Shanming Wu, Nan Jiang, Maorong Wang, Zhaohua Zhang, Feng Lin, Shaojie Xin, Yongfeng Yang, Baoshen Shen, Hong Ren
    Medicine.2019; 98(1): e13983.     CrossRef
  • Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance
    Dong Yun Kim, Hye Won Lee, Jeong Eun Song, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang‐Hyub Han, Jun Yong Park
    Journal of Medical Virology.2018; 90(3): 497.     CrossRef
  • Step-down Strategy in Antiviral Resistant Chronic Hepatitis B Patients Who Achieved Viral Suppression With Rescue Combination Therapy
    Dong Yun Kim, Jun Yong Park
    Future Virology.2018; 13(10): 711.     CrossRef
  • Efficacy and safety of three adefovir‐based combination therapies in HBeAg‐positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy
    M.‐L. Wang, E.‐Q. Chen, D.‐M. Zhang, L.‐Y. Du, L.‐B. Yan, T.‐Y. Zhou, X.‐Z. Lei, B.‐J. Lei, J.‐J. Lu, J. Liao, H. Tang
    Journal of Viral Hepatitis.2017; 24(S1): 21.     CrossRef
  • 13,143 View
  • 161 Download
  • 12 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Clinical features and outcomes of gastric variceal bleeding: retrospective Korean multicenter data
Moon Young Kim, Soon Ho Um, Soon Koo Baik, Yeon Seok Seo, Soo Young Park, Jung Il Lee, Jin Woo Lee, Gab Jin Cheon, Joo Hyun Sohn, Tae Yeob Kim, Young Suk Lim, Tae Hyo Kim, Tae Hee Lee, Sung Jae Park, Seung Ha Park, Jin Dong Kim, Sang Young Han, Chang Soo Choi, Eun Young Cho, Dong Joon Kim, Jae Seok Hwang, Byoung Kuk Jang, June Sung Lee, Sang Gyune Kim, Young Seok Kim, So Young Kwon, Won Hyeok Choe, Chang Hyeong Lee, Byung Seok Kim, Jae Young Jang, Soung Won Jeong, Byung Ho Kim, Jae Jun Shim, Yong Kyun Cho, Moon Soo Koh, Hyun Woong Lee
Korean J Hepatol 2013;19(1):36-44.
Published online March 25, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.1.36
Background/Aims

While gastric variceal bleeding (GVB) is not as prevalent as esophageal variceal bleeding, it is reportedly more serious, with high failure rates of the initial hemostasis (>30%), and has a worse prognosis than esophageal variceal bleeding. However, there is limited information regarding hemostasis and the prognosis for GVB. The aim of this study was to determine retrospectively the clinical outcomes of GVB in a multicenter study in Korea.

Methods

The data of 1,308 episodes of GVB (males:females=1062:246, age=55.0±11.0 years, mean±SD) were collected from 24 referral hospital centers in South Korea between March 2003 and December 2008. The rates of initial hemostasis failure, rebleeding, and mortality within 5 days and 6 weeks of the index bleed were evaluated.

Results

The initial hemostasis failed in 6.1% of the patients, and this was associated with the Child-Pugh score [odds ratio (OR)=1.619; P<0.001] and the treatment modality: endoscopic variceal ligation, endoscopic variceal obturation, and balloon-occluded retrograde transvenous obliteration vs. endoscopic sclerotherapy, transjugular intrahepatic portosystemic shunt, and balloon tamponade (OR=0.221, P<0.001). Rebleeding developed in 11.5% of the patients, and was significantly associated with Child-Pugh score (OR=1.159, P<0.001) and treatment modality (OR=0.619, P=0.026). The GVB-associated mortality was 10.3%; mortality in these cases was associated with Child-Pugh score (OR=1.795, P<0.001) and the treatment modality for the initial hemostasis (OR=0.467, P=0.001).

Conclusions

The clinical outcome for GVB was better for the present cohort than in previous reports. Initial hemostasis failure, rebleeding, and mortality due to GVB were universally associated with the severity of liver cirrhosis.

Citations

Citations to this article as recorded by  Crossref logo
  • Treatment of Gastric Varices
    Thomas J. Wang, Marvin Ryou
    Current Hepatology Reports.2024; 23(2): 287.     CrossRef
  • Endoscopic Treatment and Prevention of Acute Variceal Hemorrhage
    Youngdae Kim
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2024; 24(1): 5.     CrossRef
  • Plug-Assisted Retrograde Transvenous Obliteration: A Modified Balloon-Occluded Retrograde Transvenous Obliteration of Gastric Varices
    Dong Il Gwon, Hyun-Ki Yoon
    Digestive Disease Interventions.2024; 08(03): 183.     CrossRef
  • Coil- and Plug-Assisted Transvenous Retrograde Obliteration (CARTO/PARTO) in the Treatment of Gastric Varices: A European Single Centre Experience
    Giuseppe Pelle, Flavio Andresciani, Massimo Messina, Silvia Nardelli, Lorenzo Ridola, Ermanno Notarianni, Adelchi Saltarelli, Stefania Gioia, Alessandro Tanzilli, Cesare Ambrogi
    Gastrointestinal Disorders.2024; 6(3): 742.     CrossRef
  • Ендоскопічне лікування кровотеч із варикозно розширених вен шлунка
    S.M. Chooklin, S.S. Chuklin, Ya.R. Dutka
    EMERGENCY MEDICINE.2022; 18(5): 44.     CrossRef
  • Diagnosis and Management of Esophageal and Gastric Variceal Bleeding: Focused on 2019 KASL Clinical Practice Guidelines for Liver Cirrhosis
    Min Kyung Park, Yun Bin Lee
    The Korean Journal of Gastroenterology.2021; 78(3): 152.     CrossRef
  • Comparison of the Effects of TIPS versus BRTO on Bleeding Gastric Varices: A Meta-Analysis
    Zi Wen Wang, Jin Chao Liu, Fang Zhao, Wen Guang Zhang, Xu Hua Duan, Peng Fei Chen, Si Fu Yang, Hong Wei Li, Fu Wen Chen, Hong Sheng Shi, Jian Zhuang Ren
    Canadian Journal of Gastroenterology and Hepatology.2020; 2020: 1.     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications

    Clinical and Molecular Hepatology.2020; 26(2): 83.     CrossRef
  • Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) Versus Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Treatment of Gastric Varices Because of Portal Hypertension
    Swathi Paleti, Venkat Nutalapati, Jihan Fathallah, Sravan Jeepalyam, Tarun Rustagi
    Journal of Clinical Gastroenterology.2020; 54(7): 655.     CrossRef
  • Endoscopic Therapy and Radiologic Intervention of Acute Gastroesophageal Variceal Bleeding
    Jeong Eun Song, Byung Seok Kim
    Clinical Endoscopy.2019; 52(5): 407.     CrossRef
  • Detection of fundic varices obturation by endoscopic ultrasound versus multidetector computed tomography
    Amr Elrabat, Salah El-Gamal, Mohammad M. Kashwaa, Mohamed M. El-Rakhawy
    The Egyptian Journal of Internal Medicine.2019; 31(4): 487.     CrossRef
  • Plug-Assisted Retrograde Transvenous Obliteration for the Treatment of Gastric Varices: The Role of Intra-Procedural Cone-Beam Computed Tomography
    Dong Il Gwon, Gi-Young Ko, Young Baek Kwon, Hyun-Ki Yoon, Kyu-Bo Sung
    Korean Journal of Radiology.2018; 19(2): 223.     CrossRef
  • Prevention and management of gastroesophageal varices
    Yeon Seok Seo
    Clinical and Molecular Hepatology.2018; 24(1): 20.     CrossRef
  • Innovative Technique for Endoscopic Placement of Sengstaken-Blakemore Tube
    Arleen M. Ortiz, Cesar J. Garcia, Mohamed O. Othman, Marc J. Zuckerman
    Southern Medical Journal.2018; 111(5): 307.     CrossRef
  • Balloon-Occluded Retrograde Transvenous Obliteration versus Transjugular Intrahepatic Portosystemic Shunt for the Management of Gastric Variceal Bleeding
    Geunwu Gimm, Young Chang, Hyo-Cheol Kim, Aesun Shin, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
    Gut and Liver.2018; 12(6): 704.     CrossRef
  • Management of different types of gastric varices with band ligation: a 3-year experience
    Waseem M. Seleem, Amr S. Hanafy
    European Journal of Gastroenterology & Hepatology.2017; 29(8): 968.     CrossRef
  • Balloon‐occluded retrograde transvenous obliteration versus transjugular intrahepatic portosystemic shunt for treatment of gastric varices due to portal hypertension: A meta‐analysis
    Yun‐Bing Wang, Jian‐Ying Zhang, Jian‐Ping Gong, Fan Zhang, Yong Zhao
    Journal of Gastroenterology and Hepatology.2016; 31(4): 727.     CrossRef
  • Usefulness of intra-procedural cone-beam computed tomography in modified balloon-occluded retrograde transvenous obliteration of gastric varices
    Edward Wolfgang Lee, Naomi So, Ryan Chapman, Justin P McWilliams, Christopher T Loh, Ronald W Busuttil, Stephen T Kee
    World Journal of Radiology.2016; 8(4): 390.     CrossRef
  • Cyanoacrylate Injection Versus Band Ligation in the Endoscopic Management of Acute Gastric Variceal Bleeding
    Weiguang Qiao, Yutang Ren, Yang Bai, Side Liu, Qiang Zhang, Fachao Zhi
    Medicine.2015; 94(41): e1725.     CrossRef
  • Novel Use of Glidescope Indirect Laryngoscopy for Insertion of a Minnesota Tube for Variceal Bleeding
    Adam B. Schlichting, Jayna M. Gardner-Gray, Gina Hurst
    The Journal of Emergency Medicine.2015; 49(1): 40.     CrossRef
  • Re-Bleeding in Patients With Cirrhosis: Evaluation of Esophageal and Gastric Variceal Bleeding and Their Relationship With a Model for the End-Stage Liver Disease (MELD) Score and Child-Pugh Score
    Mohsen Ebrahimi, Hamidreza Reihani, Mohammadreza Sheikhian, Ehsan Bolvardi, Masumeh Pashayi, Elham Pishbin
    Razavi International Journal of Medicine.2014;[Epub]     CrossRef
  • Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension
    Jae Hyun Kim, Jung Min Kim, Youn Zoo Cho, Ji Hoon Na, Hyun Sik Kim, Hyoun A Kim, Hye Won Kang, Soon Koo Baik, Sang Ok Kwon, Seung Hwan Cha, Young Ju Kim, Moon Young Kim
    Clinical and Molecular Hepatology.2014; 20(4): 376.     CrossRef
  • The secondary prophylactic efficacy of beta-blocker after endoscopic gastric variceal obturation for first acute episode of gastric variceal bleeding
    Moon Han Choi, Young Seok Kim, Sang Gyune Kim, Yun Nah Lee, Yu Ri Seo, Min Jin Kim, Sae Hwan Lee, Soung Won Jeong, Jae Young Jang, Hong Soo Kim, Boo Sung Kim
    Clinical and Molecular Hepatology.2013; 19(3): 280.     CrossRef
  • 13,118 View
  • 86 Download
  • Crossref

The Korean Journal of Hepatology Elsewhere

Citations

Citations to this article as recorded by  Crossref logo
  • Sorafenib induces autophagic cell death and apoptosis in hepatic stellate cell through the JNK and Akt signaling pathways
    Huiyao Hao, Di Zhang, Junli Shi, Yan Wang, Lei Chen, Yongze Guo, Junji Ma, Xiaoyu Jiang, Huiqing Jiang
    Anti-Cancer Drugs.2016; 27(3): 192.     CrossRef
  • 6,888 View
  • 48 Download
  • Crossref
Original Article
Effect of alcohol on the development of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis: a cross-sectional case-control study
Oh Sang Kwon, Young Kul Jung, Yun Soo Kim, Sang Gyune Kim, Young Seok Kim, Jung Il Lee, Jin Woo Lee, Young Soo Kim, Byung Chul Chun, Ju Hyun Kim
Korean J Hepatol 2010;16(3):308-314.
Published online September 30, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.3.308
Background/Aims

Whether alcohol intake increases the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection remains controversial. The aim of this study was to determine the effect of alcohol intake on the development of HCC.

Methods

Between January 2006 and August 2008, 146 patients with an initial diagnosis of HCC who were hospitalized in 3 major hospitals in the Incheon area were enrolled as cases. Another 146 cirrhotic patients, who matched the cases by age and sex, were enrolled as controls. All cases and controls were HBsAg positive, and had a history of lifetime alcohol intake.

Results

The cases and controls were aged 53±8 and 53±9 years (mean±SD), respectively, with each group comprising 118 males and 28 females. The basal laboratory data, distribution of Child-Pugh class, HBeAg positivity (31.5% vs. 37.7%), HBV DNA level (5.74±2.35 vs. 5.98±2.29 log10 copies/mL), and proportion with a lifetime alcohol intake of more than 292 kg (30.8% vs. 34.9%) did not differ between cases and controls. The cumulative alcohol intake and the proportion of heavy drinkers did not differ between the two groups in male patients.

Conclusions

Alcohol intake might not increase the risk of HCC in patients with HBV infection.

Citations

Citations to this article as recorded by  Crossref logo
  • Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease
    Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li
    Biomedicine & Pharmacotherapy.2025; 188: 118191.     CrossRef
  • High level of serum Cripto-1 in hepatocellular carcinoma, especially with hepatitis B virus infection
    Yingyu Zhang, Hongqin Xu, Xiumei Chi, Yuxiang Fan, Ying Shi, Junqi Niu
    Medicine.2018; 97(35): e11781.     CrossRef
  • Molecular Basis of Alcohol-Related Gastric and Colon Cancer
    Hye-Kyung Na, Ja Lee
    International Journal of Molecular Sciences.2017; 18(6): 1116.     CrossRef
  • Histological improvement following administration of autologous bone marrow‐derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study
    Yoon Ok Jang, Young Ju Kim, Soon Koo Baik, Moon Young Kim, Young Woo Eom, Mee Yon Cho, Hong Jun Park, So Yeon Park, Bo Ra Kim, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Eun Hee Choi, Yong Man Kim
    Liver International.2014; 34(1): 33.     CrossRef
  • Decreased expression of the Nkx2.8 gene correlates with tumor progression and a poor prognosis in HCC cancer
    Lei Qu, Biao Deng, Yue Zeng, Zhongwei Cao
    Cancer Cell International.2014;[Epub]     CrossRef
  • The effect of coffee consumption on the development of hepatocellular carcinoma in hepatitis B virus endemic area
    Eun Sun Jang, Sook‐Hyang Jeong, Sang Hyub Lee, Sung Ho Hwang, So Yeon Ahn, Jaebong Lee, Young Soo Park, Jin Hyoek Hwang, Jin‐Wook Kim, Nayoung Kim, Dong Ho Lee, Hyun Young Kim
    Liver International.2013; 33(7): 1092.     CrossRef
  • Liver Cancer and Alcohol
    Priya Grewal, Vijay Anand Viswanathen
    Clinics in Liver Disease.2012; 16(4): 839.     CrossRef
  • Decreased expression of ALDH1L1 is associated with a poor prognosis in hepatocellular carcinoma
    Xiao-Qian Chen, Juan-Ru He, Hui-Yun Wang
    Medical Oncology.2012; 29(3): 1843.     CrossRef
  • Downregulation of Polo-Like Kinase 4 in Hepatocellular Carcinoma Associates with Poor Prognosis
    Lili Liu, Chris Zhiyi Zhang, Muyan Cai, Jia Fu, George Gong Chen, Jingping Yun, Shree Ram Singh
    PLoS ONE.2012; 7(7): e41293.     CrossRef
  • 9,027 View
  • 66 Download
  • Crossref